The War on Zika Just Hit "DEFCON 1" – and This Biotech "Frontrunner" Is Poised to Cash In

Earlier this week, Inovio Pharmaceuticals Inc. (Nasdaq: INO) announced that it dosed the first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.

The announcement caught my eye for several reasons...

  1. MULLEN93904 | August 1, 2016

    Very informative article as usual.

Leave a Reply

Your email address will not be published. Required fields are marked *


Some HTML is OK